Trial Profile
To evaluate safety and efficacy of axitinib in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2017
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 01 Oct 2017 Results assessing safety and efficacy of axitinib in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer, were published in the European Journal of Endocrinology.
- 05 Oct 2015 New trial record